Form 4: Recursion Pharma Exec's Pre-Planned Share Sales

A Recursion Pharmaceuticals executive disclosed pre-planned sales of Class A Common Stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Najat Khan, Chief R&D Commercial Officer and Director of Recursion Pharmaceuticals, Inc. (RXRX), reported changes in beneficial ownership.
• On August 15, 2025, 3,789 shares of Class A Common Stock were withheld by the Issuer at a price of $5.64 per share to satisfy tax withholding and remittance obligations related to the net settlement of restricted stock units.
• On August 18, 2025, 36,599 shares of Class A Common Stock were sold by the Issuer at a price of $5.524 per share to satisfy tax withholding and remittance obligations in connection with the vesting of restricted stock units.
• These transactions were made pursuant to a Rule 10b5-1(c) pre-planned contract, instruction, or written plan.
• Following these transactions, Najat Khan beneficially owns 668,197 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of non-discretionary insider transactions related to tax obligations from RSU vesting, which is neutral in sentiment.

Positives

• The transactions are part of a pre-planned Rule 10b5-1 plan, indicating a structured approach to equity management rather than discretionary sales.
• The sales are specifically for tax withholding obligations related to restricted stock unit vesting, which is a common and routine event for executives receiving equity compensation.

Negatives

• The transactions result in a reduction of the executive's direct beneficial ownership of Class A Common Stock by a total of 40,388 shares.

Future Outlook

The filing indicates that the reported transactions are part of a pre-planned contract or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

Routine insider transactions, particularly those related to tax obligations from equity vesting, are common across all industries, including the biotechnology and pharmaceutical sectors. These types of sales are generally not indicative of management's sentiment about the company's future prospects, unlike discretionary sales.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for executive stock transactions is a standard corporate governance practice, widely adopted by publicly traded companies to allow insiders to sell shares without concerns about insider trading allegations, especially for routine events like tax withholding.

Stakeholder Impact

• Shareholders: The executive's direct ownership stake is slightly reduced, but this is a common occurrence due to tax obligations on equity compensation and is not typically seen as a negative signal.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, SEC Form 4, Insider Trading, Stock Sales, Restricted Stock Units, Tax Withholding, 10b5-1 Plan, Najat Khan, Biotechnology, Pharmaceuticals